QTc interval in the assessment of cardiac risk

Cardiac Electrophysiology Review

Volumn 6, Issue 3, 2002, Pages 289-294

  Elming, Hanne ^a   Brendorp, Bente ^b   Køber, Lars ^a   Sahebzadah, Najia ^c   Torp Petersen, Christian ^b  

^a Rigshospitalet   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Arrhythmia; Cardiac risk; Mortality; QT interval; Torsade de pointes

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOFETILIDE; ENALAPRIL; KETOCONAZOLE; MACROLIDE; PSYCHOTROPIC AGENT; TERFENADINE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; HEART ARRHYTHMIA; HEART REPOLARIZATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; ISCHEMIC HEART DISEASE; LONG QT SYNDROME; MORTALITY; PROGNOSIS; QT INTERVAL; RISK ASSESSMENT; SUDDEN DEATH; TORSADE DES POINTES;

CARDIOVASCULAR DISEASES; DEATH, SUDDEN, CARDIAC; DIABETES COMPLICATIONS; ELECTROCARDIOGRAPHY; HUMANS; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT; TACHYCARDIA, VENTRICULAR; VENTRICULAR FUNCTION;

EID: 0036753574     PISSN: 13852264     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016345412555     Document Type: Article

References (51)

1. Exner DV, Klein GJ, Prystowsky EN. Primary prevention of sudden death with implantable defibrillator therapy in patients with cardiac disease. Circulation 2001;104:1564-1570.
2. Greene H. Sudden arrhythmic cardiac death-mechanism, resuscitation and classification: The seattle perspective. Am J Cardiol 1990;65: 4B-12B.
3. Valenzuela TD, Roe DJ, Nichol G, Clark LL, Spaite DW, Hardman RG. Outcomes of rapid defibrillation by security officers after cardiac arrest in casinos. N Eng J Med 2001;343:1206-1209.
4. Köber L, Torp-Pedersen C, Pedersen OD, Hoiberg S, Camm AJ. Importance of congestive heart failure and interaction of congestive heart failure and left ventricular systolic function on prognosis in patients with acute myocardial infarction. Am J Cardiol 1996;78:1124-1128.
5. Surawicz B, Knoebel S. Long QT: Good, Bad or indifferent? J Am Coll Cardiol 1984;4:398-413.
6. Haverkamp W, Breithardt G, Camm AJ, Janse M, Rosen MR, Antzelevitch C, Escande D, Franz M, Malik M, Moss AJ, Shah R. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications. Eur Heart J 2000;21:1216-1231.
7. Kaprilian R, Wickenden AD, Kassini Z, Parker TG, Liu PP, Backx PH. Relationship between K+ channel down-regulation and [Ca+]i in rat ventricular myocytes following myocardial infarction. J Physiol 1999;15:229-245.
8. Elming H, Holm E, Jun L, Torp-Pedersen C, Köber L, Kirchhoff M, Malik M, Camm J. The prognostic value of the QT interval and QT interval dispersion in all-cause and cardiac mortality and morbidity in a population of Danish citizens. Eur Heart J 1998;19:1391-1400.
9. Schwartz PJ, Wolf S. QT interval prolongation as predictor of sudden death in patients with myocardial infarction. Circulation 1978;57:1074-1077.
10. Ahnve S, Helmers C, Lundmann T, Rehnquist N, Sjögren A. QTc intervals in acute myocardial infarction: First-year prognostic implications. Clin Cardiol 1980;3:303-308.
11. Peters RW, Byington RP, Barker A, Yusuf S. Prognostic value of prolonged ventricular repolarisation following myocardial infarction: The BHAT experience. J Clin Epidemiol 1990;43;167-172.
12. Siltanen P, Pohjola-Sintonen S, Haapakoski J, Makijarvi M, Pajari R. The mortality predictive power of discharge electrocardiogram after first acute myocardial infarction. Am Heart J 1985;109: 1231-1237.
13. Wheelan K, Mukharji J, Rude RE, Poole WK, Gustafson N, Thomas LJ, Strauss HW, Jaffe AS, Muller JE, Roberts R, Croft CH, Passamani ER, Willerson JT. Sudden death and its relation to QT interval prolongation after acute myocardial infarction: Two year follow-up. Am J Cardiol 1986; 57:745-750.
14. Ahnve S, Lundmann T, Shoaleh-var M. The relationship between QT interval and ventricular arrhythmias in acute myocardial infarction. Acta Med Scand 1978;204:17-19.
15. Taylor GJ, Crampton RS, Gibson RS, Stebbins PT, Waldman M, Beller GA. Prolonged QT interval at onset of acute myocardial infarction in predicting early phase ventricular tachycardia. Am Heart J 1981;102:16-24.
16. Gaudron P, Kugler I, Hu K, Bauer W, Eillers C, Ertl G. Time course of cardiac structural, functional and electrical changes in asymptomatic patients after myocardial infarction. J Am Coll Cardiol 2001;38:33-40.
17. Bonnemeier H, Hartmann F, Wiegand UK, Bode F, Katus HA, Richardt G. Course and prognostic implications of QT interval and QT interval variability after primary coronary angioplasty in acute myocardial infarction. J Am Coll Cardiol 2001;37: 44-50.
18. Brendorp B, Elming H, Li Jun, Köber L, Malik M, Jensen GB, Torp-Pedersen C. QTc interval as a guide to select those patients with congestive heart failure and reduced left ventricular function who will benefit from antiarrhythmic treatment with dofetilide. Circulation 2001;13:1422-1427.
19. Torp-Pedersen C, Möller M, Bloch-Thomsen PE. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish investigations of arrhythmia and mortality on dofetilide study group. N Eng J Med 1999;341:857-865.
20. Brooksby P, Batin PD, Nolan J. The relationship between QT intervals and mortality in ambulant patients with chronic heart failure. Eur Heart J 1999;20:1335-1341.
21. Tomaselli GF, Beuckelmann DJ, Calkins HG, Berger RD, Kessler PD, Lawrence JH, Kass D, Feldman AM, Marban E. Sudden cardiac death in heart failure. Circulation 1994;90:2534-2539.
22. Dovel HC, Nul DR, Grancelli HO, Varini SD, Soifer S, Corrado G, Scapin O, Perrone SV. Nonsustained ventricular tachycardia in severe heart failure. Independent marker of increased mortality due to sudden death. Circulation 1996;94: 3198-3203.
23. Brown DV, Giles W, Greenlund KJ, Valdez R, Croft JB. Impaired fasting glucose, diabetes mellitus, and cardiovascular disease risk factors are associated with prolonged QTc duration. Results from the Third National Health and Nutrition Examination Survey. J Cardiovasc Risk 2001;8:227-233.
24. Rossing P, Breum L, Major-Pedersen A, Sato A, Winding H, Pietersen A, Kastrup J, Parving HH. Prolonged QTc interval predicts mortality in patients with Type 1 diabetes. Diabet Med 2001;18:199-205.
25. Gonin JM, Kadrofske MM, Schmaltz S, Bastyr E, Vinik AI. Corrected QT interval prolongation as diagnostic tool for assessment of cardiac autonomic neuropathy in diabetes mellitus. Diabetes Care 1990;13:68-71.
26. Erwing DJ, Boland O, Nielson JM, Cho CG, Clarke BF. Autonomic neuropathy, QT interval lengthening, and unexpected deaths in male diabetic patients. Diabetologia 1991;34:182-185.
27. Jermendy G, Toth L, Voros P, Koltai MZ, Pogatsa G. Cardiac autonomic neuropathy and QT interval length. A follow-up study in diabetic patients. Acta Cardiol 1991;46:189-200.
28. Sawicki PT. Mortality in diabetic nephopathy: The importance of the QT interval. Nephrol Dial Transplant 1996;11:1514-1515.
29. Messerli FH, Grodzicki T. Hypertension, left ventricular hypertrophy, ventricular arrhythmias and sudden death. Eur Heart J 1992;13:66-69.
30. Facchini M, Malfatto G, Ciambellotti F, Riva B, Bragato R, Branzi G, Leonetti G. Marhers of electrical instabililty in hypertensive patients with and without ventricular arrhythmias. Are they useful in identifying patients with different risk profiles? J Hypertens 2000;18:763-768.
31. Oikarinen L, Nieminen MS, Viitasalo M, Toivonen L, Wachtell K, Papademetriou V, Jern S, Dahlöf B, Devereux RB, Okin PM. Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study. J Hypertens 2001;19:1883-1891.
32. Perkiömäki JS, Ikäheimo MJ, Pikkujämsä SM, Rantala A, Lilja M, Kesäniemi A, Huikuri HV. Dispersion of the QT interval and autonomic modulation of heart rate in hypertensive men with and without left ventricular hypertrophy. Hypertension 1996;28:16-21.
33. Dahlöf B. Regression of left ventricular hypertrophy-are there differences between anti-hypertensive agents? Cardiology 1992;81:307-315.
34. Gonzalez-Juanatey JR, Garcia-Acuana JM, Pose A, Varela A, Calvo O, Cabezas-Cerrato J, de la Pena MG. Reduction of QT and QTc dispersion during treatment of systemic hypertension with enalapril. Am J Med 1998;15:170-174.
35. Siscovick DS, Raghunathan TE, Rautaharju P, Psaty BM, Cobb LA, Wagner EH. Clinically silent electrocardiographic abnormalities and risk of primary cardiac arrest among hypertensive patients. Circulation 1996;94:1329-1333.
36. El-Sherif N, Turitto G. The long QT syndrome and torsade de pointes. Pace 1999;22:91-110.
37. Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long QT syndrome. An update. Circulation 1993;88:782-784.
38. Moss AJ, Schwartz PJ, Crampton RS. The long QT syndrome. Prospective longitudinal study of 328 families. Circulation 1991;84:1136-1144.
39. Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, Denjoy I. Genophenotype correlation in the long-QT syndrome. Circulation 2001;103:89-95.
40. Benn M, Hansen PS, Pedersen AK. QT dispersion in patients with arrhythmogenic right ventricular dysplasia. Eur Heart J 1999;20:764-770.
41. Maron BJ, Oliviotto I, Spirito P, Casey S, Bellone P, Gohman TE, Graham KJ, Burton DA, Cecchi F. Epidemiology of hypertrophic cardiomyopathy-related death. Circulation 2000;102:858-864.
42. Elliott PM, Blanes J, Mahon N, Poloniecki J, McKenna W. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001; 357:420-424.
43. Fei L, Slade AK, Grace AA, Malik M, Camm AJ, McKenna W. Ambulatory assessment of the QT interval in patients with hypertrophic cardiomyopathy: Risk stratification and effect of low dose amiodarone. Pace 1994;17:2222-2227.
44. Maron BJ, Leyhe MJ 3rd, Casey SA, Gohman TE, Lawler CM, Crow RS, Maron MS, Hodges M. Assessment of QT dispersion as a prognostic marker for sudden death in a regional nonreferred hypertrophic cardiomyopathy cohort. Am J Cardiol 2001;1:114-115.
45. Viskin S. Long QT syndromes and torsade de pointes. Lancet 1999;354:1625-1633.
46. MacNeil D, Davis RO, Deitchman D. Clinical safety profile of sotalol in the treatment of arrhythmias. Am J Cardiol 1993;72:44A-50A.
47. Waldo AL, Camm. J, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 2001;348:7-12.
48. Committee for proprietary medicinal products points to consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. Pamphlet
49. Bednar MM, Harrigan EP, Anziano RJ, Camm AJ, Ruskin JN. The QT interval. Prog Cardiovasc Dis 2001;43:1-45.
50. The Cast investigators. Cardiac Arrhythmia Suppression Trial (CAST). N Eng J Med 1989;406-412.
51. Julian DG, Camm AJ, Frangin G, Janse MJ, Schwartz PJ, Simon P. Randomised trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction. Lancet 1997;349:667-674.